AI Article Synopsis
- The study aimed to assess sTNF-RI as a potential biomarker for kidney involvement in patients with systemic lupus erythematosus (SLE), focusing on those with lupus nephritis and those without renal issues.
- Results showed significantly higher levels of plasma sTNF-RI in patients with lupus nephritis compared to those without kidney issues and healthy controls, indicating a strong link to disease activity and renal function.
- The findings suggest that sTNF-RI could serve as an independent risk factor for renal involvement, leading to the development of a practical nomogram for predicting disease activity in SLE patients based on specific risk factors.
Article Abstract
Objectives: The goal of our study was to evaluate the potential role of sTNF-RI as a biomarker of renal involvement in SLE patients and active SLE.
Methods: The study sample consisted of two cohorts. The discovery cohort included 16 SLE patients without renal involvement (non-LN), 60 lupus nephritis (LN) patients and 21 healthy controls (HCs) and the replication cohort included 18 SLE non-LN patients, 116 LN patients and 36 HCs.
Results: The sTNF-RI levels differed significantly in the discovery cohort. The plasma sTNF-RI levels were higher in LN patients than in non-LN patients ( = .009) and HCs ( = 4 × 10). Plasma sTNF-RI levels were significantly higher in non-LN patients than in HCs ( = .03). The finding was confirmed in independent replication cohort (LNs . non-LN, = 4.053 × 10; LNs . HCs, = 2.395 × 10; non-LN HCs, = 2.51 × 10). The plasma sTNF-RI levels were associated with disease activity, renal function in SLE patients and urine protein in LN patients. The multivariate analysis revealed that high sTNF-RI was an independent risk factor for renal involvement. The multivariate logistic regression results suggested that high TNF-RI, high systolic blood pressure, high serum creatinine, low C4 and positive anti-dsDNA were independent risks of active SLE patients. A nomogram was constructed based on the results of multivariate logistic regression analysis and it was practical in predicting the risk of the active SLE patients. Immunohistochemistry suggested that the expression of TNF-RI in the kidney was increased.
Conclusions: Plasma sTNF-RI might be a good biomarker of renal involvement and disease activity in SLE patients.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10035946 | PMC |
| http://dx.doi.org/10.1080/0886022X.2023.2174355 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Racial differences in clinical trial perceptions among a large, predominantly Black cohort of people with systemic lupus erythematosus in the Southeastern USA.
Lupus Sci Med
January 2025
Division of Rheumatology, Emory University, Atlanta, Georgia, USA.
Objective: Black people in the USA have a higher incidence and severity of SLE and worse outcomes, yet they are significantly under-represented in SLE clinical trials. We assessed racial differences in clinical trial perceptions among a large cohort of predominantly Black people with SLE.
Methods: Georgians Organised Against Lupus (GOAL) is a population-based, prospective cohort of people with a validated diagnosis of SLE living in Atlanta.
Severe childhood SLE with refractory autoimmune hemolytic anemia-a therapeutic challenge.
BMJ Case Rep
January 2025
Dermatology, Venereology and Leprosy, AIIMS Rishikesh, Rishikesh, Uttarakhand, India
Paediatric Systemic lupus erythematosus (SLE) constitutes 10 to 20% of cases of SLE with more severe disease and higher mortality. We report a case of an adolescent girl with SLE with multisystem involvement who was started on hydroxychloroquine and oral prednisolone. However, due to persistent worsening of skin lesions and falling cell counts, pulsed dexamethasone was initiated which showed improvement in the skin lesions, cell counts, proteinuria and pleural effusion but there was a persistent fall in the haemoglobin.
View Article and Find Full Text PDFUtilisation patterns of immunomodulators and pregnancy outcomes in systemic lupus erythematosus: Insights from Korean national data.
Lupus
January 2025
College of Pharmacy, Chung-Ang University, Seoul, South Korea.
Objectives: To investigate the trends in immunomodulator use and pregnancy outcomes among pregnant women with systemic lupus erythematosus (SLE), a condition requiring medication to maintain disease activity.
Methods: This descriptive study used data from the National Health Information Database in Korea from 2002 to 2018. We included 5,044 pregnancies initiated between 2005 and 2017 in 3,120 SLE patients.
Assessing the relation between systemic lupus erythematosus and metabolic syndrome in Syria: a cross-sectional study.
BMC Rheumatol
January 2025
Endocrinology Department, Damascus University, Damascus, Syria.
Background: Systemic Lupus Erythematosus (SLE) affects all organ systems. As a result, fat intake and sedentary life are evident in the modern world. The prevalence of metabolic syndrome, with its components, increased, leading to increased mortality.
View Article and Find Full Text PDFBlood DNA virome associates with autoimmune diseases and COVID-19.
Nat Genet
January 2025
Department of Statistical Genetics, Osaka University Graduate School of Medicine, Suita, Japan.
Aberrant immune responses to viral pathogens contribute to pathogenesis, but our understanding of pathological immune responses caused by viruses within the human virome, especially at a population scale, remains limited. We analyzed whole-genome sequencing datasets of 6,321 Japanese individuals, including patients with autoimmune diseases (psoriasis vulgaris, rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), pulmonary alveolar proteinosis (PAP) or multiple sclerosis) and coronavirus disease 2019 (COVID-19), or healthy controls. We systematically quantified two constituents of the blood DNA virome, endogenous HHV-6 (eHHV-6) and anellovirus.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!